Powder: -20°C for 3 years | In solvent: -80°C for 1 year
L-732138 是选择性有效和竞争性神经激肽-1受体拮抗剂,IC50为 2.3 nM,可减轻痛觉过敏并具有抗肿瘤作用。它在克隆的人 NK-1受体中的效力比在克隆大鼠 NK-1受体中高 200 倍,比人类 NK-2 和 NK-3 受体高 1000 倍以上。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 679 | 现货 | ||
2 mg | ¥ 996 | 现货 | ||
5 mg | ¥ 1,800 | 现货 | ||
10 mg | ¥ 2,880 | 现货 | ||
25 mg | ¥ 4,450 | 现货 | ||
50 mg | ¥ 6,680 | 现货 | ||
100 mg | ¥ 8,830 | 现货 | ||
500 mg | ¥ 17,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,960 | 现货 |
产品描述 | L-732138 is a potent and competitive antagonist of neurokinin-1 (NK-1) receptor(IC50 : 2.3 nM) |
靶点活性 | NK1:2.3 nM |
体外活性 | L-732,138 against three human melanoma cell lines (COLO 858, MEL HO, COLO 679).?L-732,138 elicits cell growth inhibition in a concentration dependent manner in the melanoma cells studied.?Moreover, L-732,138 blocks SP mitogen stimulation.?The specific antitumor action of L-732,138 occurred through the NK-1 receptor and melanoma cell death was by apoptosis[1]. |
体内活性 | L-732138?Abolished the vagally-induced plasma leakage in tracheobronchial tissues, and dose-dependently inhibited the LPS enhanced vagally-induced plasma exudation in traceobronchial tissues[2]. |
细胞实验 | Cell Line:COLO 858, MEL HO and COLO 679 cells. Concentration:0 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM. Incubation Time:First doubling time[1]. |
动物实验 | Animal Model:Male Dunkin-Hartley guinea-pigs (350-500 g) injected with lipopolysaccharide (LPS)[3].Dosage:10-4 mol/kg ,10-3 mol/kg and 10-2 mol/kg. Administration:Intravenous injection; for 15 minutes[2] |
分子量 | 472.38 |
分子式 | C22H18F6N2O3 |
CAS No. | 148451-96-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.72 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1169 mL | 10.5847 mL | 21.1694 mL | 52.9235 mL |
5 mM | 0.4234 mL | 2.1169 mL | 4.2339 mL | 10.5847 mL | |
10 mM | 0.2117 mL | 1.0585 mL | 2.1169 mL | 5.2923 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
L-732138 148451-96-1 GPCR/G Protein Neuroscience Neurokinin receptor cytotoxicity vagally-induced NK receptor Neurokinin Receptor Inhibitor ntravenously lipopolysaccharide plasma Tachykinin receptor stimulation L 732138 mitogen peralgesia inhibit Antitumorhy L732138 apoptotic inhibitor